Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lupin Limited ( (IN:LUPIN) ) has issued an announcement.
Lupin Limited announced that its CEO, Vinita Gupta, has been named to the 2026 CNBC Changemakers list of Women Transforming Business, recognizing her role in making medicines more accessible and affordable for Americans. The honor underscores Lupin’s rapid ascent under her leadership to become the third-largest generic medicine supplier to the U.S. by volume and highlights its growing portfolio in complex generics, inhalation therapies, and biosimilars.
Gupta’s strategic emphasis on the U.S. market includes the FDA approval in late 2025 of Lupin’s first biosimilar Pegfilgrastim, reinforcing its push into high-value, specialty medicines. Her drive to expand domestic manufacturing through a planned state-of-the-art inhalation facility in Coral Springs, Florida, is positioned to bolster U.S. medicine security, increase production of key respiratory drugs such as Albuterol, and improve access for patients, further strengthening Lupin’s competitive standing and stakeholder confidence.
More about Lupin Limited
Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, with products distributed in more than 100 markets worldwide. The company focuses on branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients, with a significant market presence in the U.S. as one of the largest suppliers of generic medicines.
Average Trading Volume: 33,145
Technical Sentiment Signal: Strong Buy
Current Market Cap: 1028.9B INR
Find detailed analytics on LUPIN stock on TipRanks’ Stock Analysis page.